BRYREL Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Bryrel, and when can generic versions of Bryrel launch?
Bryrel is a drug marketed by Sanofi Aventis Us and is included in one NDA.
The generic ingredient in BRYREL is piperazine citrate. There are eighteen drug master file entries for this compound. Additional details are available on the piperazine citrate profile page.
Summary for BRYREL
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 50 |
Formulation / Manufacturing: | see details |
DailyMed Link: | BRYREL at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for BRYREL
US Patents and Regulatory Information for BRYREL
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sanofi Aventis Us | BRYREL | piperazine citrate | SYRUP;ORAL | 017796-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |